研究内容・実績

研究テーマ

この5年間で当施設にて行った強皮症や筋炎に関する研究テーマについてご紹介します。
病気の原因究明や新規治療法の開発を目指し、当施設で独自に基礎的な研究を行っております。
また、多くの患者さんや医療従事者に、少しでも臨床の現場で貢献できるように、早期診断・予後予測の方法や個々の患者さんに適した医療提供の確立を目指し、国内・国外の多くの専門施設と協力して、多施設共同研究を行っております。

強皮症

強皮症の病態解明と新規治療法の開発
強皮症早期診断基準案の有用性に関する前向き研究
強皮症に合併する間質性肺疾患における血中KL-6の有用性評価
超早期および早期強皮症の進展阻止を目指した治療標的の同定
欧州強皮症臨床試験・研究グループ(EUSTAR)による強皮症調査研究

筋炎

筋炎特異自己抗体の病原性に関する検討
皮膚筋炎における自己抗体解析およびHLA解析による疾患感受性の検討
悪性腫瘍関連筋炎の臨床的特徴と病態の解明
特異的自己抗体と筋炎関連間質性肺病変の胸部画像所見との関連
筋炎多発性筋炎/皮膚筋炎合併間質性肺炎の予後予測因子の同定

肺高血圧症・間質性肺疾患

肺高血圧症の治療法を比較検討する多施設共同症例登録研究
肺高血圧症患者レジストリ(Japan Pulmonary Hypertension registry: JAPHR)
膠原病関連肺病変の臨床的特徴と病態に関与する分子の同定
膠原病関連間質性肺疾患における診療アウトカムの解明と予後不良因子の同定

業績

また、過去5年間の上記と関連した業績を以下にご紹介します。

強皮症

2019年

論文(英文)
  1. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, for the SENSCIS trial investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 2019; 380(26): 2518-2528. doi: 10.1056/NEJMoa1903076
  2. Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth M, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, and Assassi S. Progression of interstitial lung disease in systemic sclerosis: the importance of pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019; 71(12): 2059-2067. doi: 10.1002/art.41020
  3. Butler E, Baron M, Fogo AB, Frech T, Ghossein C, Hachulla E, Hoa S, Johnson SR, Khanna D, Mouthon L, Nikpour M, Proudman S, Steen V, Stern E, Varga J, Denton CP, Hudson M, and Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group. Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology. Arthritis Rheuamtol. 2019; 71(6): 964-971. doi: 10.1002/art.40809
  4. Elhai M, Hoffmann-Vold AM, Avouac J, Pezet S, Cauvet A, Leblond A, Fretheim H, Garen T, Kuwana M, Molberg Ø, and Allanore Y. Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2019; 71(6): 972-982. doi: 10.1002/art.40815
  5. Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre-Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Chotchaeva F, Lescoat A, Siegert E, Castellví I, Airò P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva LP, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Rosa Pozzi M, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Lévy V, Allanore Y for EUSTAR network. Outcomes of systemic sclerosis patients treated with rituximab in contemporary practice: a prospective cohort study. Ann. Rheum. Dis. 2019; 78(7): 979-987. doi: 10.1136/annrheumdis-2018-214816
  6. Yasuoka H, Tam YY, Okazaki Y, Tamura Y, Matsuo K, Feghali-Bostwick C, Takeuchi T, and Kuwana M. Fos-related antigen-1 transgenic mouse as a model for systemic sclerosis: a potential role of M2 polarization. J. Scleroderma Relat. Disord. 2019; 4(2): 137-148. doi:org/10.1177/239719831983814
  7. Shima Y, Kawaguchi Y, and Kuwana M. Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify endotype to tocilizumab therapy. Mod. Rheumatol. 2019; 29(1): 134-139. doi: 10.1080/14397595.2018.1452178
  8. Bruni C, Shirai Y, Kuwana M, and Matucci-Cerinic M. Cyclophosphamide: similarities and differences in the treatment of SSc and SLE. Lupus. 2019; 28(5): 571-574. doi: 10.1177/0961203319840433
  9. Hamaguchi Y, Kuwana M, and Takehara K. Performance evaluation of a line blot assay for detection of anti-PM-Scl antibody in Japanese patients with systemic sclerosis. Int. J. Rheum. Dis. 2019; 22(9): 1746-1751. doi: 10.1111/1756-185X.13638
論文(和文)
  1. 桑名正隆: 全身性強皮症(全身性硬化症). 私の治療. 週刊 日本医事新報49(66): 50, 2019. 6.
  2. 桑名正隆: 全身性強皮症による肺高血圧症. 日本臨牀77(7): 1140-1146, 2019. 7.
  3. 桑名正隆: 強皮症診療の現状と課題. 医学と薬学76(10): 1411-1417, 2019. 10.
著書(邦文)
  1. 桑名正隆: 強皮症. 南学正臣総編集「内科学書 改訂第9版」中山書店、東京、pp238-243, 2019. 8.
  2. 桑名正隆: 膠原病. 南学正臣総編集「内科学書 改訂第9版」中山書店、東京、pp310-311, 2019. 8.
  3. 桑名正隆: 全身性強皮症. 浦部晶夫、島田和幸、川合眞一総編集「今日の処方 改訂第6版」南江堂、東京、pp517-520, 2019. 3.
  4. 桑名正隆: 全身性強皮症と呼吸器症状・心症状. 尹浩信、竹原和彦、佐藤伸一、桑名正隆編著「強皮症のすべてがわかる本」保健同人社、東京、pp76-84, 2019. 6.
  5. 桑名正隆: 混合性結合組織病. 福井次矢、高木誠、小室一成総編集. 「今日の治療指針Vol62 私はこう治療している」、医学書院、東京、pp884-885, 2020, 1.
  6. 桑名正隆: 全身性強皮症. 「診療ガイドライン UP-TO-DATE 2020-2021」、メディカルレビュー社、大阪、pp661-665, 2020. 2.
学会
  1. Kuwana M: Are we on the verge of cracking the nut in systemic sclerosis? . 21st Asia Pacific League of Associations for Rheumatology Congress. APLAR2019(Brisbane/ Australia). 2019. 4.
  2. Kuwana M: Evening Meeting; Low risk≠No risk: Further exploration of AMBITION CTD data. (includes Q&A and discussion). Annual European Congress of Rheumatology. EULAR2019 (Madrid/ Spain). 2019. 6.
  3. Lin C.J.F. Khanna, J. Goldin, G. Kim, Kuwana M, Allanore, Y Batalov A, Butrimiene I, Carreira P, Matucci-Cerinic M, Distler O, Martinovic Kaliterna D, MihaiC.-M, Mogensen M, Olesinska M, Pope J.E, Riemekasten G, Rodriguez-Reyna T.S, Santos M.J, van Laar J, Spotswood H, Siegel J, Jahreis A, Furst D, C.P. Denton C.P: Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis. ATS2019. (Dallas, TX). 2019. 5.
  4. Distler O, Highland K.B, Gahlemann M, Azuma A, Fischer A, Mayes M.D, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher T.M: Nintedanib Reduces Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Results of the SENSCIS Trial. ATS2019. (Dallas, TX). 2019. 5.
  5. Distler O, Allanore Y, Denton C, Kuwana M, Matucci-Cerinic M, Pope J.E, Oliveira Pena J. DE, Laapas K, Yao Z, Behmenburg F, Hemmrich M, Khanna D: Efficacy and Safety of Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease (SSc-ILD): Results from the Phase IIb RISE-SSc Study. ATS2019. (Dallas, TX). 2019. 5.
  6. Distler O, Highland K.B, Gahlemann M, Azuma A, Fischer A, Mayes M, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Kuwana M, Maher T.M: Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): The SENSCIS Trial. ATS2019. (Dallas, TX). 2019. 5.
  7. Hemmrich M, Distler O, Allanore Y, Denton C, Kuwana M, Matucci-Cerinic M, Pope JE, de Oliveira Pena J, Laapas K, Yao Z, Khanna D. Efficacy and Safety of Riociguat in Patients With Early Diffuse Cutaneous Systemic Sclerosis: Results from the RISE-SSc study, A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study. 9th International Conference on cGMP (Mainz/ Germany). 2019. 6.
  8. Maher T, Highland K, Gahlemann M, Azuma A, Fischer A, Mayes M, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Kohlbrenner V, Kuwana M, Distler O, on behalf of SENSCIS trial investigators: Gastrointestinal adverse events in patients with systemic Sclerosis-Associated Interstitial Lung Disease (SSC-ILD) treated with nintedanib: Date from the senscis trial. (18. Scleroderma, myositis and related syndromes) EULAR2019 (Madrid/ Spain). 2019. 6.
  9. Khanna D, Allanore Y, Denton C, Kuwana M, Matucci-Cerinic M, Pope J, J. de Oliveria Pena, Laapas K, Yao Z, Hemmrich M, Distler O: The Effects of riociguat on raynaud’s phenomenon and digital ulcers in patients with diffuse systemic sclerosis: results from The phase IIB RISE-SSc study. (18. Scleroderma, myositis and related syndromes) EULAR2019 (Madrid/ Spain). 2019. 6.
  10. Distler O. Highland K, Gahlemann M, Azuma A, Fischer A, Mayes M, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Kuwana M, Maher T on behalf of SENSCIS trial investigators: Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. EULAR2019 (Madrid/ Spain). 2019. 6.
  11. Kuwana M, Blair C, Langley J, Takahashi T, Coghlan G: Utility of risk stratification in predicting outcomes of initial monotherapy versus combination therapy in pulmonary arterial hypertension associated with connective tissue disease: a post-hoc analysis of the AMBITION study. EULAR2019 (Madrid/ Spain). 2019. 6.
  12. Distler O, Allanore Y, Denton C, Kuwana M, Matucci- Cerinic M, Pope J, de Oliveria Pena J, Laapas K, Yao Z, Behmenburg F, Hemmrich M, Khanna D: Efficacy and safety of riociguat in patients with early diffuse cutaneous systemic sclerosis and interstitial lung disease (SSc-ILD): results from the phase IIB RISE-SSc study. EULAR2019 (Madrid/ Spain). 2019. 6.
  13. Highland K, Distler O, Gahlemann M, Azuma A, Fischer A, Mayes M, Raghu G, Sauter W, Girard M, Kohlbrenner V, Clerisme-Beaty E, Stowasser S, Kuwana M, Maher T on behalf of SENSCIS trial investigators: Safety profile of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and idiopathic pulmonary fibrosis. EULAR2019 (Madrid/ Spain). 2019. 6.
  14. Khanna D, Lin C, Goldin J, Kim G, Kuwana M, Allanore Y, Batalov A, Butrimiene I, Carreira P, Matucci- Cerinic M, Distler O, Martinović Kaliterna D, Mihai C, Mogensen M, Olesińska M, Pope J, Riemekasten G, Rodriguez-Reyne T, Santos M, van Laar J, Spotswood H, Siegel J, Jahreis A, Furst D, Denton C: Preservation of lung function observed in a phase 3 randomized controlled trial of tocilizumab for the treatment of early SSc. EULAR2019 (Madrid/ Spain). 2019. 6.
  15. Kuwana M, Highland K , Gahlemann M , Denton C , Fischer A , Mayes M , Steen V , Khanna D, Allanore Y , Girard M , Alves M , Stowasser S and Distler O: Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial. 2019ACR/ARP Annual Meeting (Atlanta, Ga). 2019. 11.
  16. Shirai Y, Kawami N, Iwakiri K and Kuwana M: Vonoprazan, a Novel Potassium-competitive Acid Blocker, for Treatment of Proton Pump Inhibitor-resistant Reflux Esophagitis in Patients with Systemic Sclerosis. 2019ACR/ARP Annual Meeting (Atlanta, Ga). 2019. 11.
  17. Shirai Y, Yasuoka H, Tamura Y and Kuwana M: Risk Assessment in Connective Tissue Disease Associated Pulmonary Arterial Hypertension. 2019ACR/ARP Annual Meeting (Atlanta, Ga). 2019. 11.
  18. Fischer A, Distler O, Khanna D, Allanore Y, Anna Maria Hoffmann-Vold, Valentini G, Maher T, Aringer M, Meng L, Alves M, Gahlemann M, Quaresma M and Kuwana M: Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom. 2019ACR/ARP Annual Meeting (Atlanta, Ga). 2019. 11.
  19. Nawata T, Suzuki M, Shirai Y and Kuwana M : Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease. 2019ACR/ARP Annual Meeting (Atlanta, Ga). 2019. 11.
  20. Mayes M, Highland K, Gahlemann M, Fischer A, Raghu G, Girard M, Alves M, Stowasser S, Distler J, Matucci-Cerinic M, Volkman E, Kuwana M and Distle Or: Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial. 2019ACR/ARP Annual Meeting (Atlanta, Ga). 2019. 11.
  21. Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton C, Distler J, Anna Maria Hoffmann-Vold, Khanna D, Mayes M, Raghu G, Vonk M, Gahlemann M, Girard M, Stowasser S, Zoz D, Fischer A and Maher T: Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial. 2019ACR/ARP Annual Meeting (Atlanta, Ga). 2019. 11.
  22. 桑名正隆: ランチョンセミナー5; 全身性硬化症の早期診断と活動性評価における現状と課題点. 第63回日本リウマチ学会総会・学術集会. (京都) 2019. 4. 15.
  23. 桑名正隆: Current problems and future direction of management of systemic sclerosis. 第63回日本リウマチ学会総会・学術集会. (京都). 2019. 4. 15. (シンポジウム4. Frontier of systemic autoimmune diseases)
  24. Ota Y、Strober W、Kitani A: PI3K-Akt pathway plays a crucial role in production of collagen in Fli1 deficient condition and its inhibitor has the therapeutic potential in treating fibrosis. 第63回日本リウマチ学会総会・学術集会. (京都). 2019. 4. 15. (International Concurrent Workshop5-5. Molecular Target)
  25. 桑名正隆、嶋良仁、田中良哉、竹原和彦、岡田法大、五十嵐弘子: 全身性強皮症(SSc)患者を対象としたトシリズマブ第Ⅲ相臨床試験の日本人集団解析. 第63回日本リウマチ学会総会・学術集会. (京都). 2019. 4. 17. (ワークショップW-58-5. 強皮症-1)
  26. 桑名正隆: ランチョンセミナー38; 全身性強皮症に伴う間質性肺疾患の疾患自然歴と進行予測. 第63回日本リウマチ学会総会・学術集会. (京都) 2019. 4. 17.
  27. 桑名正隆: 教育研修講演19; 続・強皮症診療のよくある10の間違い. 第63回日本リウマチ学会総会・学術集会. (京都) 2019. 4. 17.
  28. 名和田隆司、白井悠一郎桑名正隆: 強皮症関連間質性疾患における経時的な胸部筋量変化の解析. 第63回日本リウマチ学会総会・学術集会. (京都). 2019. 4. 17. (ワークショップW-77-2. 強皮症-3)
  29. 白井悠一郎桑名正隆: 強皮症(SSc)における食道機能と関連した臨床特徴の解析. 第63回日本リウマチ学会総会・学術集会. (京都). 2019. 4. 17. (ワークショップW-77-5. 強皮症-3)
  30. 桑名正隆: EASOPH Joint Meeting in Hamamatsu; PH management and activity of PH society in Japan. 第4回日本肺高血圧・肺循環学会学術集会. (浜松). 2019. 6. 20.
  31. 桑名正隆: ランチョンセミナー5; CTD-PAHにおける最新エビデンスと治療戦略—AMBITIONスタディサブ解析より—. 第4回日本肺高血圧・肺循環学会学術集会. (浜松). 2019. 6. 22.
  32. 白井悠一郎: 症例から学ぶ肺高血圧症(PH)の診断. 第4回日本肺高血圧・肺循環学会学術集会. (浜松). 2019. 6. 22. (肺高血圧診断スキルアップセミナー)
  33. 桑名正隆: 強皮症の病態関連遺伝子. 第40回日本炎症・再生医学会. (神戸). 2019. 7. 16. (シンポジウムSO1-4)
  34. 白井悠一郎桑名正隆: トシリズマブ投与の減量・中止が早期びまん皮膚硬化型強皮症(dcSSc) を再燃させる. 第47回日本臨床免疫学会総会. (札幌). 2019. 10. 17.

2018年

論文(英文)
  1. Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, Takehara K, Hatano M, Fujimoto M, Mugii N, and Ihn H. Diagnostic criteria, severity classification, and guidelines of systemic sclerosis. J. Dermatol. 2018; 45(6): 633-691. doi:10.1111/1346-8138.14162.
  2. Salazar GA, Kuwana M, Wu M, Estrada-Y-Martin RM, Ying J, Charles J, Mayes MD, and Assassi S. KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease. J. Rheumatol. 2018; 54(8): 1153-1158. doi: 10.3899/jrheum.170518.
論文(和文)
  1. 桑名正隆: 強皮症. リウマチ・膠原病の最新情報(Ⅳ)ドクターズサロン62(7): 48-51, 2018. 6.
著書(和文)
  1. 桑名正隆: 全身性強皮症. 最新醫学別冊「診療と治療のABC139」. 最新医学社, 大阪, pp134-142, 2018. 10.
  2. 桑名正隆: 膠原病肺/強皮症に伴う間質性肺炎. 三嶋理晃総編集「間質性肺炎・肺線維症と類縁疾患」中山書店, 東京, pp257-264, 2018. 10.
  3. 桑名正隆: 全身性強皮症. 門脇孝、神庭重信、工藤正俊、倉林正彦、田中良哉、畠清彦、三嶋理晃監修「リウマチ・膠原病 診断と治療のABC139」、最新医学者、大阪、pp134-142, 2018, 10.
  4. 桑名正隆: 全身性強皮症. 浦部晶夫、島田和幸、川合眞一総編集「今日の処方 改訂第6版」南江堂、東京、pp517-520, 2019. 3.
学会
  1. Kuwana M: Diagnosis of systemic sclerosis, update 2018. in association with SNUH Rheumatology symposium “Systemic Sclerosis, A to Z” (Seoul). 2018. 4.
  2. Kuwana M: SSc-PAH: pathogenesis. OPTIMUM symposium. (Seoul). 2018. 4.
  3. Kuwana M: Current management of pulmonary arterial hypertension in Japan: Rheumatologist perspectives. 2018 TPHA Annual Scientific Meeting. (Taichung, Taiwan). 2018. 4.
  4. Yasuoka H, Sakata K, Yoshimoto K, Yamaoka K, Kuwana M, Takeuchi T: Activated platelets are increased in circulation of patients with systemic sclerosis and associated with clinical characteristics. EULAR2018 (Amsterdam). 2018. 6.
  5. Kuwana M: Clinical management of SSc-ILD: from rheumatologist perspective. Expert meeting for SSc-ILD. 20th Asia Pacific League of Associations for Rheumatology Congress. APLAR2018 (Kaohsiung, Taiwan). 2018. 9.
  6. Kuwana M: How to evaluate CTD features in patients with ILD/IPAF. ILD Symposium. 20th Asia Pacific League of Associations for Rheumatology Congress. APLAR2018 (Kaohsiung, Taiwan). 2018. 9.
  7. Khanna D, Celia J. F. Lin, Kuwana M, Allanore Y, Batalov A, Butrimiene I, Carreira P, Marco Matucci Cerinic, Distler O, Dusanka Martinović Kaliterna, Mihai C, Mogensen M, Olesinska M, Janet E. Pope, Riemekasten G, Tatiana S. Rodriguez-Reyna, Maria José Santos, Jacob van Laar, Spotswood H, Jeffrey Siegel, Jahreis A, Daniel E. Furst and Christopher P. Denton : Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial. 2018 ACR/ARHP Annual Meeting (Chicago, IL). 2018. 10.
  8. Allanore Y, Christopher P. Denton, Kuwana M, Matucci-Cerinic M, Janet E. Pope , Pena J, Laapas K, Yao Z and Dinesh Khanna: Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc). 2018 ACR/ARHP Annual Meeting (Chicago, IL). 2018. 10.
  9. Elizabeth R. Volkmann, Donald P. Tashkin, Kuwana M, Li N, Charles J, Faye N. Hant, Galina S. Bogatkevich, Akter T, Roth M, Hyun J. Grace Kim, Goldin J, Khanna D, Philip J. Clements, Daniel E. Furst, Elashoff R, Silver R and Assassi S: Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression. 2018 ACR/ARHP Annual Meeting (Chicago, IL). 2018. 10.
  10. Khanna D, Allanore Y, Christopher P. Denton, Kuwana M, Marco Matucci-Cerinic5, Janet E. Pope6, Janethe Pena7, Kaisa Laapas8, Zhen Yao9 and Oliver Distler10: The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study. 2018 ACR/ARHP Annual Meeting (Chicago, IL). 2018. 10.
  11. Oliver Distler, Yannick Allanore, Christopher P. Denton, Kuwana M, Marco Matucci-Cerinic, Janet E. Pope, Janethe Pena, Kaisa Laapas, Zhen Yao and Dinesh Khanna: Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc). 2018 ACR/ARHP Annual Meeting (Chicago, IL). 2018. 10.
  12. Khanna D, Allanore Y, Christopher P. Denton, Kuwana M, Marco Matucci-Cerinic, Janet E. Pope, Pena J, Laapas K, Yao Z and Oliver Distler: The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study. 2018 ACR/ARHP Annual Meeting (Chicago, IL). 2018. 10.
  13. Kuwana M: Management of systemic sclerosis: current status and future directions. The 38th Korean College of Rheumatology Annual Scientific Symposium. (Gangneung/ Korea). 2018. 11.
  14. Kuwana M: Biomarker in SSc-associated interstitial lung disease. The 9th Symposium of International Network of Scleroderma Clinical Care and Research. InSCAR (Shanghai/ China). 2019. 3.
  15. 桑名正隆: 教育研修講演; 強皮症診療によくある10の間違い. 第62回日本リウマチ学会総会・学術集会. (東京). 2018. 4. 28.
  16. 桑名正隆: ランチョンセミナー37; 全身性強皮症(全身性硬化症)の早期診断・評価. 第62回日本リウマチ学会総会・学術集会. (東京). 2018. 4. 28.
  17. 安岡秀剛、坂田康明、桑名正隆、竹内勤: 全身性硬化症における血小板の活性化状態と臨床的特徴との関連. 第62回日本リウマチ学会総会・学術集会. (東京). 2018. 4. 27.
  18. 白井悠一郎桑名正隆: 強皮症(SSc)における症候性皮下石灰沈着の臨床特徴. 第62回日本リウマチ学会総会・学術集会. (東京). 2018. 4.
  19. 桑名正隆: 教育講演: 肺高血圧症を合併する膠原病診断のポイント. 第3回日本肺高血圧・肺循環学会学術集会. (大阪). 2018. 6. 23.
  20. 桑名正隆、Blair Christiana、Langley Jonathan、Coghlan Gerry: AMBITION:mlTT集団でのCTD-PAHサブ解析結果. 第3回日本肺高血圧・肺循環学会学術集会. (大阪). 2018. 6. 23.
  21. 白井悠一郎、田中住明、山崎宜興、深谷修作、川口鎮司、坂尾誠一郎、田邉信宏、桑名正隆、巽浩一郎: 膠原病に伴う肺動脈性肺高血圧症に対する肺血管拡張薬のメタ解析. 第3回日本肺高血圧・肺循環学会学術集会. (大阪). 2018. 6. 23.
  22. 山崎宜興、深谷修作、白井悠一郎、田中住明、川口鎮司、坂尾誠一郎、田邉信宏、桑名正隆、巽浩一郎: CTD-PAHに対する免疫抑制療法: Systematic reviewによる検討. 第3回日本肺高血圧・肺循環学会学術集会. (大阪). 2018. 6. 23.
  23. 安岡秀剛、白井悠一郎、田村雄一、川口鎮司、天野宏一、岡田正人、桑名正隆: 膠原病(CTD)に伴う軽症肺動脈性肺高血圧症に対する介入試験. 第3回日本肺高血圧・肺循環学会学術集会. (大阪). 2018. 6. 23.
  24. 桑名正隆: 全身性強皮症. 第39回日本炎症・再生医学会. (東京). 2018. 7. 11. (シンポジウム12. 膠原病における治療最前線)
  25. 内山竣介、白井悠一郎、名和田隆司、小林政司、五野貴久、岳野光洋、桑名正隆: 全身性エリテマトーデス(SLE) 併発を契機に肺動脈性肺高血圧症(PAH) 顕在化した原発性胆汁性胆管炎(PBC) に伴う門脈圧亢進症の1例. 第29回日本リウマチ学会関東支部学術集会. (東京). 2018. 12. 8.

2017年

論文(英文)
  1. Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, and Rubin LJ. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann. Rheum. Dis. 2017; 76(7): 1219-1227. doi: 10.1136/annrheumdis-2016-210236.
  2. Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, Kawaguchi Y, Matucci-Cernic M, Ohmura K, Riemekasten G, Kawasaki A, Airo P, Horita T, Oka A, Hachulla E, Yoshifuji H, Caramaschi P, Hunzelman N, Baron M, Atsumi T, Hassouns P, Torii T, Takahashi M, Tabara Y, Shimizu M, Tochimoto A, Ayuzawa N, Yanagida H, Furukawa H, Tohma S, Hasegawa M, Fujimoto M, Ishikawa O, Yamamoto T, Goto D, Asano Y, Jinnin M, Endo H, Takahashi H, Takehara K, Sato S, Ihn H, Raychaudhuri S, Liao K, Gregersen P, Tsuchiya N, Riccieri V, Melchers I, Valentini G, Cauvet A, Martinez M, Mimori T, Matsuda F, and Allanore Y. Trans-ethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Ann. Rheum. Dis. 2017; 76(6): 1150-1158. doi: 10.1136/annrheumdis-2016-210645.
  3. Shirai Y, and Kuwana M. Complex pathophysiology of pulmonary hypertension associated with systemic sclerosis: potential unfavorable effects of pulmonary vasodilators. J. Scleroderma Rel. Dis. 2017; 2(2): 92-99. doi:10.5301/jsrd.5000235.
  4. Kuwana M. A to-do list at diagnosis of systemic sclerosis in case of positive anti-RNA polymerase III antibodies. J. Rheumatol. 2017; 44(5): 550-552. doi: 10.3899/jrheum.170037.
  5. Kuwana M. Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting. J. Nippon Med. Sch. 2017; 84(2): 56-63.
  6. Oka A, Asano Y, Hasegawa M, Fujimoto M, Ishikawa O, Kuwana M, Kawaguchi Y, Yamamoto T, Takahashi H, Goto D, Endo H, Jinnin M, Mano S, Hosomichi K, Mabuchi T, Takahashi-Ueda M, Nakagawa S, Beck S, Bahram S, Takehara K, Sato S, and Ihn H. RXRB is a novel MHC-encoded susceptibility gene associated with anti-topoisomerase I antibody-positive systemic sclerosis. J. Invest. Dermatol. 2017; 137(9): 1878-1886. doi: 10.1016/j.jid.2017.04.028.
  7. Varga J, Trojanowska M, and Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J. Scleroderma Relat. Disord. 2017; 2(3): 137-152. doi: 10.5301/jsrd.5000249.
  8. Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M: Predictors for favorable responses to immunosuppressive treatment in pulmonary arterial hypertension associated with connective tissue disease. Circ J. 2018; 82(2): 546-554. doi: 10.1253/circj.CJ-17-0351
論文(和文)
  1. 白井悠一郎: 強皮症における肺高血圧症-その多様性と治療戦略.リウマチ科 2017; 57(4): 430-436. 2017. 4.
  2. 桑名正隆: 早期のKL-6上昇が強皮症に伴う間質性肺疾患の肺機能低下の予測因子になる. リウマチ科58(3): 319-325, 2017. 9.
  3. 桑名正隆: 全身性強皮症−現状の課題と将来展望—. SRL宝函38(2): 21-27, 2017. 7.
  4. 桑名正隆: 高齢者の抗セントロメア抗体陽性、レイノー症候群の治療法. ドクターサロン61(7): 20-23, 2017. 7.
  5. 桑名正隆: 難治性肺高血圧症診療の経験から学ぶ. Pulmonary Hypertension Update 3(2): 14-24, 2017. 11.
  6. 桑名正隆: 抗RNAポリメラーゼⅢ抗体と強皮症腎クリーゼ. リウマチ科59(2): 138-144, 2018. 2.
  7. 白井悠一郎: 強皮症の血管障害におけるneuropilin-1の意義. リウマチ科58(6): 625-629, 2017. 12.
  8. 白井悠一郎桑名正隆: 関節痛をどう診るか 強皮症. 成人と生活習慣病47(9): 1161-1164, 2017. 9.
著書(英文)
  1. Kuwana M and Medsger TA, Jr. The clinical aspects of autoantibodies. In “Scleroderma -From Pathogenesis to Comprehensive Management”. Second edition. Edited by Varga J, Denton CP, Wigley FM, Allanore Y, and Kuwana M: Springer, New York, USA. 2017: p207-220.
  2. Shah A and Kuwana M. Cancer in Systemic Sclerosis. In “Scleroderma -From Pathogenesis to Comprehensive Management”. Second edition. Edited by Varga J, Denton CP, Wigley FM, Allanore Y, and Kuwana M: Springer, New York, USA. 2017: p525-532.
著書(和文)
  1. 白井悠一郎桑名正隆: CTD-PAH治療におけるリオシグトへの期待. 福田恵一、巽浩一郎監修「sGC刺激薬リオシグトによる肺高血圧症治療〜基礎から実臨床まで〜」, メディカルレビュー社, 大阪, pp102-108, 2017. 4.
  2. 桑名正隆: 強皮症の自然歴と早期診断. 熊谷俊一編集「別冊・医学のあゆみ 自己免疫疾患」, 医歯薬出版, 東京, pp53-58, 2017. 8.
  3. 桑名正隆: 全身性強皮症. 矢崎義雄監修「内科学 第11版」, 朝倉書店, 東京, pp1254-1258. 2017. 4.
  4. 白井悠一郎桑名正隆: 膠原病に伴う肺動脈性肺高血圧症—基礎知識—. 筒井裕之、伊藤正明編集「循環器診療 ザ・ベーシック 肺高血圧症」, メジカルビュー社, 東京, pp38-45, 2018. 3.
  5. 白井悠一郎桑名正隆: 膠原病に伴う肺動脈性肺高血圧症—実践—. 筒井裕之、伊藤正明編集 「循環器診療 ザ・ベーシック 肺高血圧症」, メジカルビュー社, 東京, pp46-53, 2018. 3.
学会
  1. Yamaguchi Y, Shirai Y, Ono J, Kawaguchi Y, Izuhara K, Kuwana M, Aihara1 M. An increased circulating level of periostin in patients with systemic sclerosis: associations with functional impairment in various affected organs. The 76th Annual Meeting of Society for Investigative Dermatology (Portland). 2017. 4.
  2. Kuwana M. Autoantibody Detection and Standardization. 2nd Global Conference on Myositis (Potomac) 2017. 5.
  3. Kuwana M: Autoantibodies in Systemic sclerosis. SNUH Rheumatology Symposium 2017. (Seoul). 2017. 6.
  4. Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, Kawaguchi Y, Matucci-Cerinic M, Ohmura K, Riemekasten G, Kawasaki A, Airo P, Horita T, Oka A, Hachulla E, Yoshifuji H, Caramaschi P, Hunzelmann N, Baron M, Atsumi T, Hassouns P, Tochimoto A, Ayuzawa N, Yanagida H, Furukawa H, Tohma S, Hasegawa M, Fujimoto M, Ishikawa O, Yamamoto T, Goto D, Asano Y, Jinnin M, Endo H, Takahashi H, Takehara K, Sato S, Ihn H, Raychaudhuri S, Liao K, Gregersen P, Tsuchiya N, Riccieri V, Melchers I, Valentini G, Cauvet A, Martinez M, Mimori T, Matsuda F, Allanore Y: Trans-ethnic meta-analysis of genome-wide association studies identifies gsdma and prdm1 as susceptibility genes to systemic sclerosis. EULAR 2017 (Madrid) 2017. 6.
  5. Sakata K, Yasuoka H, Koseki M, Yoshimoto K, Kuwana M, Takeuchi T: Circulating microparticle subsets are associated with patients with extended fibrotic phenotype in systemic sclerosis. EULAR 2017 (Madrid) 2017. 6.
  6. Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M: Screening of pulmonary arterial hypertension in patients with systemic sclerosis using detect algorithm - validation in the cohort of japanese single center. EULAR 2017 (Madrid) 2017. 6.
  7. Salazar G, Kuwana M, Wu M, Martin RE, Ying J, Charles J, C. Bellocchi, Mayes M, Assassi S: KL6 and not CCL-18 is a predictor of early progression in systemic sclerosis related interstitial lung disease. EULAR 2017 (Madrid) 2017. 6.
  8. Takei H, Yasuoka H, Shirai Y, Sugiura H, Yamaoka K, Kuwana M, Takeuchi T. Patients with earlier and milder disease with interstitial lung involvement in systemic sclerosis have better response to immunosuppressive treatment. 15th International Workshop on Scleroderma Research (Pittsburgh). 2017.8
  9. Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M. Validation of DETECT algorithm in patients with systemic sclerosis - validation in a cohort of Japanese single center. 15th International Workshop on Scleroderma Research (Pittsburgh). 2017.8
  10. Sakata K, Yasuoka H, Koseki M, Yoshimoto K, Kuwana M, Takeuchi T: Circulating microparticle subsets are associated with extended fibrotic phenotype in systemic sclerosis. 15th International Workshop on Scleroderma Research (Pittsburgh). 2017.8
  11. Kuwana M: Immunogenetics of Scleroderma. APLAR2017 (Dubai, U.A.E.). 2017. 10.
  12. Yasuoka H, Takei H, Shirai Y, Yamaoka K, Kuwana M, and Takeuchi T: Characteristic of Pulmonary Arterial Hypertension in Patients with Anti-U1RNP Antibody-Positive-Connective Tissue Diseases Is Determined By the Underlying Disease Rather Than Autoantibody Profile. 2017 ACR/ARHP Annual Meeting (San Diego). 2017. 11.
  13. Kuwana M: New Autoantibodies, organ involvement and disease progression. 5th Systemic Sclerosis World Congress (Bordeaux). 2018. 2.
  14. Kuwana M, Blair C, Langley J, Coghlan J: Ambition Study: Initial Combination Therapy of AmbriSentan and Tadalafil in Connective Tissue Disease associated Pulmonary Arterial HypertenSion (ctd- pah) in the Modified Intention to Treat Population. 5th Systemic Sclerosis World Congress. (Bordeaux). 2018. 2.
  15. Elhai M, Distler O, Smith V, Matucci-Cerinic M, Alegre-Saancho J.J, Truchetet M.E, Braun-Moscovici Y, Iannone F, Chotchaeva F, Lescoat A, Siegert E, Castellvi I, Airo P, Vettori S, Hachulla E, Erler A, Ananieva L, Krusche M, Lopez-Longo FJ F.J, Kuwana M, Allanore Y: Rituximab in Systemic Sclerosis: Safety and Efficacy Data from the Eustar Network. 5th Systemic Sclerosis World Congress (Bordeaux). 2018. 2.
  16. Yasuoka H, Takei H, Shirai Y, Yamaoka K, Kuwana M, Takeuchi T: Characteristics of Anti-uirnp-Antibody- Positive Patients with Pulmonary Arterial Hypertension are Influenced by the Presence or Absence of Systemic Sclerosis Features. 5th Systemic Sclerosis World Congress (Bordeaux). 2018. 2.
  17. Shirai Y, Okazaki Y, Kuwana M: Clinical Characteristics of Critical Limb Ischemia in Systemic Sclerosis. 5th Systemic Sclerosis World Congress (Bordeaux). 2018. 2.
  18. 桑名正隆: 膠原病性高血圧の生命予後改善のために –我々リウマチ医ができること−. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  19. 桑名正隆: 全身性強皮症の早期診断と治療. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  20. 桑名正隆: 強皮症に伴う間質性肺炎. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  21. 桑名正隆: 多発性筋炎・皮膚筋炎に合併する間質性肺炎治療の実際. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  22. 安岡秀剛、白井悠一郎、竹内勤、桑名正隆: DETECTアルゴリズムによる全身性強皮症(SSc)患者に合併する肺動脈性肺高血圧(PAH)のスクリーニング〜当施設でのvalidation. 第61回日本リウマチ学会総会・学術集会. (福岡) . 2017. 4.
  23. 白井悠一郎、竹内勤、桑名正隆: 強皮症における重症虚血肢の臨床特徴. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  24. 坂田康明、安岡秀剛、小関真子、吉本桂子、桑名正隆、竹内勤: 全身性強皮症の病態における血漿マイクロパーティクルの関与. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  25. 行木紳一郎、桑原理志、福井潤、小中八郎、前田悠一、桑名正隆、藤原弘士: 血栓性微小血管障害症治療後に急速に進行する皮膚硬化にシクロホスファミド大量静注療法および少量ステロイド奏功した早期全身性強皮症の一例. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  26. 白井悠一郎: 膠原病に伴う肺動脈性肺高血圧症(CTD-PAH)の診断・治療up to date. 第65回日本心臓病学会学術集会. (大阪). 2017. 10.

2016年

論文(英文)
  1. Kuwana M, Shirai Y, and Takeuchi T. Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J. Rheumatol. 2016; 43(10): 1825-1831.
  2. Hamaguchi Y, Sumida T, Kawaguchi Y, Ihn H, Tanaka S, Asano Y, Motegi S, Kuwana M, Endo H, and Takehara K. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: prospective, multicenter, open-label study. J. Dermatol. 2017; 44(1): 13-17. doi: 10.1111/1346-8138.13497.
  3. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger TA, Jr, Merkel PA, Pope JE, Seibold JR, Steen VD, Denton CP, on behalf of the Scleroderma Clinical Trials Consortium and the World Scleroderma Foundation. Use and standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J. Scleroderma Rel. Dis. 2017; 2(1): 11-18.
  4. Atanelishvili I, Shirai Y, Akter T, Buckner T, Noguchi A, Silver RM, Bogatkevich GS. M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo. Transl Res. 2016 Apr;170:99-111. doi: 10.1016/j.trsl.2015.12.009.
  5. Atanelishvili I, Shirai Y, Akter T, Noguchi A, Ash KT, Misra S, Ghatak S, Silver RM, Bogatkevich GS. D1398G Variant of MET Is Associated with Impaired Signaling of Hepatocyte Growth Factor in Alveolar Epithelial Cells and Lung Fibroblasts. PLoS One. 2016 Sep 1;11(9):e0162357. doi: 10.1371/journal.pone.0162357.
論文(和文)
  1. 桑名正隆: 全身性強皮症. 内科 117(4) (2016年増大号) 2016; 901-907.
  2. 桑名正隆: 膠原病性肺高血圧症. 血栓と循環2016; 24(1): 76-79.
  3. 桑名正隆: 強皮症における分子標的治療の可能性. リウマチ科2016; 55(3): 292-297.
  4. 桑名正隆: 全身性硬化症(強皮症)の早期診断と治療. 日本内科学会雑誌2016; 105(9): 1864-1869.
  5. 桑名正隆: 強皮症の自然歴と早期診断. 週間 医学のあゆみ 2016; 258(10): 945-950.
  6. 白井悠一郎桑名正隆: 慢性炎症と線維化.別冊BIO Clinica 2016; 5(3): 18-22.
  7. 白井悠一郎.プロスタグランジン治療に伴う副作用の管理.Pulmonary Hypertension Update 2016; 2(2): 38-45.
著書(英文)
  1. Kuwana M. Endothelial progenitor cells. In “Systemic Sclerosis: Basic and Translational Research”. Edited by Takehara K, Fujimoto M, and Kuwana M: Springer, London, UK. 2016: p39-56.
  2. Kuwana M. Immunodiagnosis of scleroderma. In “Manual of Molecular and Clinical Laboratory Immunology”. 8th edition. Edited by Detrick B, Hamilton R, and Schmitz J: ASM Press, Washington DC, USA. 2016: p888-896. doi:10.1128/9781555818722.ch91
著書(和文)
  1. 桑名正隆: 肺臓. 佐藤伸一編集「強皮症の基礎と臨床」, 医薬ジャーナル社, 大阪, 2016: p.127-137.
  2. 桑名正隆: 間質性肺疾患. 佐藤伸一編集「強皮症の基礎と臨床」, 医薬ジャーナル社, 大阪, 2016: p194-203.
  3. 桑名正隆: 強皮症 (全身性硬化症) (SSc). 上阪等編集「膠原病・リウマチ・アレルギー研修ノート」, 診断と治療社, 東京 ,2016: p319-323.
  4. 白井悠一郎桑名正隆: 強皮症. 「病気とくすり」, 南山堂, 東京, 2017: p246-249.
学会
  1. Kuwana M. Predictors of digital ulcer in SSc: endothelial progenitor cells and circulating biomarkers. 18th Asia Pacific League of Associations for Rheumatology Congress. (Shanghai). 2016. 9.
  2. Kuwana M. Clinical aspects and pathogenic roles of autoantibodies in systemic sclerosis. The 13th International Workshop on Autoantibodies and Autoimmunity. (Kyoto). 2016. 10.
  3. Kuwana M. Autoantibodies in systemic sclerosis (tentative). The 13th International Workshop on Autoantibodies and Autoimmunity. (Kyoto). 2016. 10.
  4. Salazar G, Kuwana M, Wu M, Jun Ying, Charles J, Maureen D Mayes and Assassi S. KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease. 80th Annual Scientific Meeting of American College of Rheumatology (Washington, DC). 2016. 11.
  5. Yamaguchi Y, Shirai Y, Ono J, Kawaguchi Y, Izuhara K, Kuwana M and Aihara M. An Increased Circulating Level of Periostin in Patients with Systemic Sclerosis: Associations with Functional Impairment in Various Affected Organs Display combined fields only if separate fields don't exist. 80th Annual Scientific Meeting of American College of Rheumatology (Washington, DC). 2016. 11.
  6. 桑名正隆: 強皮症. 第56回日本呼吸器学会学術講演会. (京都). 2016. 4.
  7. 桑名正隆: 教育講演; 全身性硬化症(強皮症)の早期診断と治療. 第113回日本内科学会総会・講演会. (東京). 2016. 4.
  8. 桑名正隆: 全身性強皮症の早期診断と治療. 第60回日本リウマチ学会総会・学術集会. (横浜). 2016. 4.
  9. 白井悠一郎、岳野光洋、竹内勤、桑名正隆: 全身性強皮症における血清KL-6値の経済的測定の臨床的意義. 第60回日本リウマチ学会総会・学術集会 (横浜). 2016. 4.
  10. 白井悠一郎、安岡秀剛、田村雄一、竹内勤、桑名正隆: 強皮症に伴う肺高血圧症における肺拡散能の経時的評価の意義. 第1回日本肺高血圧・肺循環学会学術集会. (東京). 2016. 10.
  11. 白井悠一郎桑名正隆: 膠原病関連肺動脈性肺高血圧症 (CTD-PAH)の予後. 第1回日本肺高血圧・肺循環学会学術集会. (東京). 2016. 10.
  12. 安岡秀剛、白井悠一郎、田村雄一、川口鎮司、天野宏一、岡田正人、桑名正隆: 膠原病合併軽症肺動脈性肺高血圧症に対する介入試験. 第1回日本肺高血圧・肺循環学会学術集会. (東京). 2016. 10.
  13. 桑名正隆白井悠一郎、安岡秀剛: 膠原病性肺高血圧症の克服への試み. 第1回日本肺高血圧・肺循環学会学術集会 (東京). 2016. 10.
  14. 桑名正隆: 教育研修講演; 強皮症治療の新たな展開. 第27回日本リウマチ学会関東支部学術集会. (東京). 2016. 12.
  15. 桑名正隆: Pulmonary Hypertension Associated with Connective Tissue Disease: Current Therapeutic Strategies and Future Perspectives. 第81回日本循環器学会学術集会. (金沢). 2017. 3.

2015年

論文(英文)
  1. Hamaguchi Y, Kodera M, Matsushita T, Usuda T, Kuwana M, Takehara K, and Fujimoto M. Clinical and immunological predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III antibodies. Arthritis Rheumatol. 2015; 67(4): 1045-1052. doi: 10.1002/art.38994.
  2. Shirai Y and Kuwana M. Reply: Assessment of elevated pentraxin 3 in systemic sclerosis (letter). Arthritis Rheumatol. 2015; 67(5):1409-1410. doi: 10.1002/art.39032.
  3. Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Fujita J, Kataoka M, Kuwana M, Satoh T, and Fukuda K. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. BMC Pulm. Med. 2015; 15: 62. doi: 10.1186/s12890-015-0037-8.
  4. Tamura Y, Kimura M, Takei M, Ono T, Kuwana M, Satoh T, Fukuda K, and Humbert M. Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. Eur. Respir. J. 2015; 46(1): 283-286. doi: 10.1183/09031936.00044915.
  5. Hamaguchi Y, Kuwana M, and Fujimoto M. Reply: Clinical and immunological predictors of scleroderma renal crisis for Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies (letter). Arthritis Rheumatol. 2015; 67(9): 2548. doi: 10.1002/art.39201.
  6. Hatano M, Yamada H, Fukuda K, Yoshioka K, Funauchi M, Kuwana M, Sata M, Taniguchi M, Nakanishi N, Saito T, Saji T, and Sasayama S. Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension. Heart Vessels. 2015; 30(6): 798-804.
  7. Kuwana M and Matucci Cerinic M. Introducing the Journal of Scleroderma and Related Disorders, a challenge for the future of our community. J. Scleroderma Rel. Dis. 2016; 1(1): 1.
論文(和文)
  1. 桑名正隆: 全身性硬化症. 高齢者のリウマチ・膠原病はこう診る. 内科2015; 115(3): 413-417.
  2. 桑名正隆: 強皮症の診断と治療. クリニシアン 2015; 636(62): 113-118.
  3. 桑名正隆: 全身性強皮症. 呼吸器内科 2015; 27(4): 256-262.
  4. 桑名正隆: 強皮症. 内科疾患の診断基準・病型分類・重症度. 内科2015; 115(6): 1161-1163.
  5. 桑名正隆: 膠原病と肺高血圧症. 分子リウマチ治療 2015; 8(2): 11-14.
  6. 桑名正隆: 強皮症. 免疫性神経疾患 基礎・臨床研究の最新知見2015; 73(7): 655-660.
  7. 桑名正隆: 膠原病に関連した肺高血圧症. 診断と治療2015; 103(6): 757-761.
  8. 白井悠一郎桑名正隆: 腸管嚢胞状気腫症の病態・診断・治療. リウマチ科 2015; 53(5): 431-435.
  9. 白井悠一郎桑名正隆: 各種疾患に伴う肺高血圧症−膠原病 2015; Heart View 19(7): 28-32.
  10. 桑名正隆: 膠原病に伴うPAH/PHの課題. Pulmonary Hypertension Update 1(Suppl) 2015; 58-62.
  11. 桑名正隆: 肺高血圧症治療のUpdate. Pulmonary Hypertension Update 2015; 1(1): 14-23.
  12. 桑名正隆: 強皮症の新たな治療概念. 臨床リウマチ2015; 27(4): 281-287.
  13. 桑名正隆: 強皮症重症例に対する治療. 分子リウマチ治療 2015; 8(4): 50-53.
  14. 白井悠一郎桑名正隆: 膠原病に伴う肺動脈性肺高血圧症の治療戦略. 医学のあゆみ 2015; 255(1): 65-69.
  15. 桑名正隆: 膠原病性肺動脈性肺高血圧症. Medical Practice 2015; 32(12): 1954-1957.
  16. 桑名正隆: 強皮症に対するLPA1阻害薬. Rhematology Clinical Research 2015; 4(3): 56-60.
  17. 桑名正隆: 膠原病に伴う肺高血圧症. medicina 2016; 53(2): 376-380.
  18. 桑名正隆: 強皮症性混合型肺高血圧症に対する病態評価と治療のポイント. 内科2016; 117(3): 449-454.
  19. 桑名正隆: 強皮症における分子標的治療の可能性. リウマチ科2016; 55(3): 292-297.
  20. 白井悠一郎: 強皮症におけるpentraxin 3の意義.リウマチ科 2016; 55(2): 209-214.
著書(和文)
  1. 桑名正隆: 膠原病および類縁疾患に伴う肺病変. 高橋和久、児玉裕三監修「EBMを活かす 呼吸器診療」, メジカルビュー社, 東京, 2015: p319-324.
  2. 桑名正隆: 間質性肺疾患の評価と治療. 三森経世、桑名正隆、松本功、保田晋助監修「リウマチ・膠原病診療ハイグレード(1巻)分子標的/Bio時代のリウマチ・膠原病治療ストラテジー」, 文光堂, 東京, 2015: p221-232.
  3. 桑名正隆: 全身性強皮症の治療にステロイドを使ってよいか?. 川合眞一監修「ステロイドのエビデンス」, 羊土社, 東京, 2015: p40-42.
  4. 桑名正隆: 膠原病に伴う配高血圧症の活動性評価や治療方針(ステロイド、免疫抑制薬、分子標的薬など)について教えてください. 監修「〜早期診断・治療のための〜肺高血圧症Q&A」, 先端医学社, 東京, 2015: p223-227.
  5. 桑名正隆: 膠原病に伴う肺高血圧症の診断と治療. 「診断と治療のABC104 肺高血圧症、最新医学社, 大阪, 2015: p191-197.
学会
  1. Yasuoka H, Tam YA, Okazaki Y, Tamura Y, Takada I, Matsuo K, Takeuchi T, Kuwana M. M2-shifted mice recapitulate remodeling of the skin and lung. Annual European Congress of Rheumatology EULAR2015 (Roma). 2015. 6.
  2. Shirai Y, Takeuchi T and Kuwana M. Clinical utility of serial KL-6 measurement in interstitial lung disease associated with systemic sclerosis. 14th International Workshop on SCLERODERMA RESEARCH (Cambridge). 2015. 8.
  3. Kuwana M, Hasegawa M, Shirai Y, Ishikawa O, Endo H, Ogawa F, Goto D, Sato S, Ihn H, Kawaguchi Y and Takehara K. Parameters That Predict Worsening of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis. 79th Annual Scientific Meeting of American College of Rheumatology (San Francisco). 2015. 11.
  4. Shirai Y, Takeuchi T and Kuwana M. Clinical Utility of Serial KL-6 Measurement in Interstitial Lung Disease Associated with Systemic Sclerosis. 79th Annual Scientific Meeting of American College of Rheumatology (San Francisco). 2015. 11.
  5. Atanelishvili I, Shirai Y, Akter T, Stolarzewicz E, Swenson RE, Silver RM, Bogatkevich GS. Inhibition of Sphingosine-1-Phosphate Signaling By AB22 As a Novel Strategy in the Treatment of Pulmonary Fibrosis Associated with Scleroderma. The 79th Annual Scientific Meeting of American College of Rheumatology (San Fransisco). 2015. 11.
  6. Yasuoka H, Tam Y. Y, Okazaki Y, Tamura Y, Matsuo K, Takeuchi T, Kuwana M. M2-Shifted Mice Recapitulate Dermal and Pulmonary Remodeling. 4th Systemic Sclerosis World Congress (Lisbon). 2016. 2.
  7. Shirai Y, Takeuchi T, Kuwana M. Efficacy and Safety of Tocilizumab in Patients with Systemic Sclerosis: Experiences in a Routine Clinical Setting. 4th Systemic Sclerosis World Congress (Lisbon). 2016. 2.
  8. Kuwan M. Anti-RNA polymerase Ⅲ antibody: from its discovery to utility in clinical practice and basic research. (Lisbon). 2016. 2.
  9. 桑名正隆: 膠原病性肺高血圧症診療における課題. 第59回日本リウマチ学会総会 (名古屋). 2015. 4.
  10. 桑名正隆: 強皮症に対するIL-6阻害療法. 第59回日本リウマチ学会総会 (名古屋). 2015. 4.
  11. 桑名正隆: 膠原病の肺高血圧症. 第59回日本リウマチ学会総会 (名古屋). 2015. 4.
  12. 桑名正隆: 教育研修講演22; 膠原病医が知っておくべき肺高血圧症の基本知識. 第59回日本リウマチ学会総会 (名古屋). 2015. 4.
  13. 桑名正隆: CTD-PAHの最新状況 / overview. 第4回日本肺循環学会・第3回日本肺高血圧学会合同学術集会. (東京). 2015. 10.
  14. 白井悠一郎、田村雄一、金子祐子、竹内勤、桑名正隆: 強皮症(SSc)における定期的な肺高血圧症スクリーニングの意義. 第4回日本肺循環学会・第3回日本肺高血圧学会合同学術集会. (東京). 2015. 10.
  15. 白井悠一郎、仁科 直、門田寛子、福栄亮介、鏑木 誠、岳野光洋、桑名正隆: トシリズマブを投与した心嚢液貯留を伴う全身性強皮症の2例. 第18回東京リウマチ膠原病研究会. (東京). 2015. 10.
  16. 桑名正隆: 教育講演; 強皮症. 第30回日本臨床リウマチ学会. (神戸). 2015. 11.
  17. 桑名正隆: 教育講演; 肺高血圧症 Update. 第30回日本臨床リウマチ学会. (神戸). 2015. 11.
  18. 白井悠一郎:Hepatocyte growth factor(HGF)受容体由来新規ペプチドによる抗線維化効果. 第2回東京理科大学・日本医科大学合同シンポジウム (東京). 2015.12.12.

筋炎

2019年

論文(英文)
  1. Gono T, Okazaki Y, Murakami A, and Kuwana M. Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody. Mod. Rheumatol. 2019; 29(1): 140-145. doi: 10.1080/14397595.2018.1452179
  2. Gono T, Tanino Y, Nishikawa A, Kawamata T, Hirai K, Okazaki Y, Shibata Y, and Kuwana M. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease. Int. J. Rheum. Dis. 2019; 22(8): 1582-1586. doi: 10.1111/1756-185X.13593
  3. Kadota H, Gono T, Shirai Y, Okazaki Y, Takeno M, and Kuwana M. Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr. Rheumatol. Rep. 2019; 21(4): 10. doi.org/10.1007/s11926-019-0811-3
  4. Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M, Kuwana M, and Ariga T. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. Mod. Rheumatol. 2019; 29(2): 351-356. doi: 10.1080/14397595.2018.1452353
  5. Aoyama J, Hayashi H, Yajima C, Takoi H, Tanaka T, Kashiwada K, Kokuho N, Terasaki Y, Nishikawa A, Gono T, Kuwana M, Saito Y, Abe S, Seike M, and Gemma A. Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations. Respir. Med. Case Rep. 2019; 26: 193-196. doi: 10.1016/j.rmcr.2019.01.012
著書(英文)
  1. Sato S, Fujimoto M, and Kuwana M. Anti-MDA5 Autoantibody. In “Myositis Handbook: An Inclusive Guide to the Inflammatory Myopathies”. Edited by Christopher-Stine and Lundberg I. Jaaypee Brothers Medical Publishers, New Delhi, India: In press.
  2. McHugh N, Zoe B, Gono T, Kuwana M, and Targoff I. The role of autoantibodies in myositis. In “Managing Myositis: A Practical Guide”. Edited by Aggarwal R and Oddis CV: Springer, London, UK: 2019: p97-106.
  3. Gono T, and Kuwana M. Role of Myositis Autoantibodies in Management and Prognosis. In “Managing Myositis: A Practical Guide”. Edited by Aggarwal R and Oddis CV: Springer, London, UK: In press.
  4. Gono T, and Kuwana M. Newer Dermatomyositis Autoantibodies: TIF1-γ, MDA5, and NXP2. In “Managing Myositis: A Practical Guide”. Edited by Aggarwal R and Oddis CV: Springer, London, UK: In press.
著書(邦文)
  1. 五野貴久: 筋炎関連間質性肺炎疾患における予後予測と治療の層別化. 「自己抗体と自己免疫2019」医学生物学研究所、愛知、pp1-8, 2019. 9.
学会
  1. Gono T, Masui K, Nishina N, Sato S and Kuwana M: Predictive Factors for Mortality in Anti-melanoma-associated Gene 5 Antibody-associated Interstitial Lung Disease. 2019ACR/ARP Annual Meeting (Atlanta, Ga). 2019. 11.
  2. Kaieda S, Gono T , Masui K, Nishina N, Sato S and Kuwana M: Surfactant Protein D as a Useful Predictor for Mortality in Myositis-associated Interstitial Lung Disease: A Dimorphic Model Based on anti-MDA5 Antibody. 2019ACR/ARP Annual Meeting (Atlanta, Ga). 2019. 11.
  3. 五野貴久: ランチョンセミナー10; 多発性筋炎・皮膚筋炎に合併する間質性肺炎治療 Update. 第63回日本リウマチ学会総会・学術集会. (京都) 2019. 4. 15.
  4. 五野貴久、仁科直、佐藤慎二、桑名正隆: 多発性筋炎・皮膚筋炎合併間質性肺病変(PM/DM-ILD)におけるカルシニューリン阻害薬の有効性の検討—シクロスポリンとタクロリムスの治療効果の比較. 第63回日本リウマチ学会総会・学術集会. (京都). 2019. 4. 15. (ワークショップW1-1: 多発性筋炎・皮膚気炎-1)
  5. 五野貴久: 教育研修講演18; 特発性炎症性筋疾患の診断と治療. 第63回日本リウマチ学会総会・学術集会. (京都) 2019. 4. 17.
  6. 門田寛子、五野貴久、山口由衣、渡邊萌理、岡崎有佳、白井悠一郎、小林政司、岳野光洋、寺井千尋、桑名正隆: 悪性腫瘍関連筋炎(CAM)における皮膚・筋症状の寛解に関する規定因子の同定. 第63回日本リウマチ学会総会・学術集会. (京都). 2019. 4. 17. (ワークショップW-69-1. 多発性筋炎・皮膚筋炎-4)
  7. 桜庭未多、門田寛子、五野貴久、山口由衣、渡邊萌理、岡崎有佳、渡邊晋二、白井悠一郎、小林政司、岳野光洋、寺井千尋、桑名正隆: 同時性重複癌を有する悪性腫瘍関連筋炎の臨床的検討. 第63回日本リウマチ学会総会・学術集会. (京都). 2019. 4. 17. (ワークショップW-69-2. 多発性筋炎・皮膚筋炎-4)
  8. 五野貴久、佐藤慎二、桑名正隆: 抗MDA5抗体陽性間質性肺疾患における予後不良因子に基づいた三剤併用療法の有効性に関する層別化. 第47回日本臨床免疫学会総会. (札幌). 2019. 10. 18.
  9. 渡邊晋二、五野貴久、川端真里佐、内山竣介、吉田晃、小林政司、白井悠一郎、岳野光洋、桑名正隆: 血栓性微小血管障害(TMA)を主病態とした抗MDA5抗体陽性皮膚筋炎(DM)の1例. 第30回日本リウマチ学会関東支部学術集会. (東京). 2019. 12. 7.
  10. 吉田晃、五野貴久、福栄亮介、川端真里佐、内山竣介、渡邊晋二、小林政司、白井悠一郎、岳野光洋、桑名正隆: 手指壊疽を呈した抗アミノアシルtRNA合成酵素(ARS)抗体陽性の一例. 第30回日本リウマチ学会関東支部学術集会. (東京). 2019. 12. 7.

2018年

論文(英文)
  1. Sato S, Hirakata M, Asano K, and Kuwana M. Anti-aminoacyl tRNA synthetase antibodies in Japanese patients with interstitial lung disease. Open J. Rheumatol. Autoimmun. Dis. 2018; 8: 34-42. doi: org/10.4236/ojra.2018.81003.
  2. Endo Y, Koga T, Suzuki T, Hara K, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, and Kawakami A. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report. Medicine (Baltimore). 2018; 97(15): e0436. doi: 10.1097/MD.0000000000010436.
  3. Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Hosono Y, Mimori T, and Kawakami A. Reccurence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report. Medicine (Baltimore). 2018; 97(26): e11024. doi: 10.1097/MD.0000000000011024.
  4. Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M, Ikeda K, Nunokawa T, Tanino Y, Asakawa K, Kaneko Y, Gono T, Ukichi T, Kaieda S, Naniwa T, Kuwana M, and A Multicentre Retrospective Cohort of Japanese Patients with Myositis-associated ILD (JAMI) Investigators. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford). 2018; 57(7):1212-1221. doi: 10.1093/rheumatology/key060.
  5. Kawasumi H, Katsumata Y, Nishino A, Hirahara S, Kawaguchi Y, Kuwana M, and Yamanaka H. Association of serum soluble CD163 with polymyositis and dermatomyositis, predominantly with anti-MDA5 antibody-positive cases. J. Rheumatol. 2018; 45(7): 947-955. doi: 10.3899/jrheum.170997.
  6. Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, Nakamura M, Zaizen Y, Nouno T, Koga T, Kawayama T, Kuwana M, Ida H, and Hoshino T. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor outcome in the chronic phase of interstitial lung disease in patients with dermatomyositis. Respir. Invest. 2018: 56(5): 464-472. doi: 10.1016/j.resinv.2018.07.007.
論文(和文)
  1. 桑名正隆: 炎症性筋疾患と自己抗体. Medical Practice 35(6): 879-884, 2018. 6.
  2. 五野貴久桑名正隆: 成人特発性炎症性筋疾患. 日本臨牀77(3): 456-461, 2019. 3.
学会
  1. Yamaguchi Y, Kuwana M, Kanaoka M, Watanabe T, Okiyama N, Gono T, Kodera M, Kambara T, Hamaguchi Y, Seishima M, Takehara K, Fujimoto M, Aihara M: DRB1 is the primary genetic locus contributing to susceptibility to dermatomyositis positive for anti-TIF1γ antibody in Japanese. International Investigative Dermatology2018. (Orlando). 2018. 5.
  2. Kadota H, Gono T, Yamaguchi Y, Watanabe E, Okazaki Y, Nakajima Y, Kobayashi S, Shirai Y, Takeno M, Terai C, Kuwana M: Initial predictors for mortality with cancer-associated myositis a multicenter retrospective cohort in Japan. EULAR2018. (Amsterdam). 2018. 6.
  3. Kaneko Y, Nunokawa T, Taniguchi Y, Yamaguchi Y, Gono T, Masui K, Kawakami A, Kawaguchi Y, Sato S, Kuwana M on behalf of JAMI investigators: Clinical characteristics of patients with cancer-associated myositis complicated by interstitial lung disease. EULAR2018 (Amsterdam/ Holland). 2018. 6.
  4. Kuwana M: Interstitial lung disease associated with systemic sclerosis: current and future approach to the management. 20th Asia Pacific League of Associations for Rheumatology Congress. APLAR2018 (Kaohsiung, Taiwan). 2018. 9.
  5. Gono T, Masui K, Nishina N, Sato S and Kuwana M: Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus. 2018 ACR/ARHP Annual Meeting (Chicago, IL). 2018. 10.
  6. Watanabe E, Gono T, Yabe H, Kuwana M, Kato K and Terai C: Elevated Serum Levels of Soluble CD146 and CD146 Autoantibody in Patients with Polymyositis/Dermatomyositis. 2018 ACR/ARHP Annual Meeting (Chicago, IL). 2018. 10.
  7. Inoue M, Uruha A, Jean-Luc Charuel4, Musset L, Suzuki S, Kuwana M, Mimori T, Nishino I: Tight association between microinfarction and capillary MAC deposition in dermatomyositis. World Muscle Society Congress (Argentine). 2018. 10.
  8. Kuwana M: How to evaluate clinical outcomes of myositis-associated interstitial lung disease. 3RD Global Conference on Myositis. GCOM2019 (Berlin/ Germany). 2019. 3.
  9. Gono T: Risk stratification in patients with anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease treated initially with intensive combination regimen. 3RD Global Conference on Myositis. GCOM2019 (Berlin/ Germany). 2019. 3.
  10. 渡邉萌理、五野貴久、阿部麻衣、渡邊晋二、矢部寛樹、桑名正隆、加藤和則、寺井千尋: 多発性筋炎/皮膚筋炎における血清CD146の検討. 第62回日本リウマチ学会総会・学術集会. (東京). 2018. 4
  11. 五野貴久、川口鎮司、川上純、佐藤慎二、桐野洋平、池田啓、布川貴博、金子祐子、仁科直、桑名正隆: 多発性筋炎・皮膚筋炎合併間質性肺病変(Myositls-ILD)における三剤併用療法の有効性の検討. 第62回日本リウマチ学会総会・学術集会. (東京). 2018. 4.
  12. 門田寛子、五野貴久、山口由衣、渡邉萌理、岡﨑有佳、小林政司、白井悠一郎、岳野光洋、寺井千尋、桑名正隆: 悪性腫瘍関連筋炎(CAM)の予後規定因子の同定. 第62回日本リウマチ学会総会・学術集会. (東京). 2018. 4.

2017年

論文(英文)
  1. Hamaguchi Y, Kuwana M, and Takehara K. Comparison of anti-OJ antibody detection assays between an immunoprecipitation assay and a line blot assay. Mod. Rheumatol. 2017; 27(3): 551-552. doi: 10.1080/14397595.2016.1213947.
  2. Kobayashi N, Tozawa Y, Ueko M, Takezaki S, Watanabe S, Iwafuchi H, Yasuda M, Kuwana M, and Ariga T. Tacrolimus in combination with methotrexate and corticosteroid for the treatment of child-onset anti-SRP antibody-positive necrotizing myopathy. Scand. J. Rheumatol. 2017; 46(5): 409-410. doi: 10.1080/03009742.2016.1241297.
  3. Chen Z, Wang Y, Kuwana M, Xu X, Hu W, Feng X, Wang H, Kimura A, and Sun L. HLA-DRB1 alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis. J. Rheumatol. 2017; 44(9): 1389-1393. doi: 10.3899/jrheum.170165.
論文(和文)
  1. 五野貴久: 多発性筋炎・皮膚筋炎におけるマクロファージ活性化症候群. リウマチ科 59(1): 21-25, 2018. 1.
著書(英文)
  1. Sato S, Fujimoto M, and Kuwana M. Anti-MDA5 Autoantibody. In “Myositis Handbook: An Inclusive Guide to the Inflammatory Myopathies”. Edited by Christopher-Stine and Lundberg I. Jaaypee Brothers Medical Publishers, New Delhi, India: In press.
学会
  1. Gono T. Kawaguchi Y, Kawakami A, Sato S, Tamura M, Ikeda K, Nunokawa T, Tanino Y, Asakawa K, Kaneko Y, Nishina N, Masui K, Kuwana M and JAMI investigators. Combined Evaluation of Myositis-Specific Autoantibodies and Serum Conventional Biomarkers Is Useful for Stratification of Prognosis in Polymyositis/Dermatomyositis With Interstitial Lung Disease. The Global Conference on Myositis 2017 (Potomac) 2017. 5.
  2. Nishina N, Sato S, Kawaguchi Y, Kawakami A, Tamura M, Ikeda K, Nunokawa T, Tanino Y, Asakawa K, Kaneko Y, Gono T, Masui K, Kuwana M, and JAMI investigators. Influence of Season and Residential Environment on Development of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Polymyositis/Dermatomyositis with Interstitial Lung Disease. 2nd Global Conference on Myositis (Potomac) 2017. 5.
  3. Kadota H, Gono T, Shirai Y, Okazaki Y, Takeno M, Kuwana M: Clinical Characteristics of Immune Checkpoint Inhibitors-Induced Myositis: A Case Report and Literature Review. APLAR2017 (Dubai, U.A.E.). 2017. 10.
  4. Gono T, Masui K, Kawaguchi Y, Ikeda K, Kawakami A, Tamura M, Tanino Y, Nunokawa T, Kaneko Y, Sato S, Asakawa K, Nishina N and Kuwana M: Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers. 2017 ACR/ARHP Annual Meeting (San Diego). 2017. 11.
  5. Watanabe E, Gono T, Watanabe S, Yabe H, Kuwana M and Terai C: Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan. 2017 ACR/ARHP Annual Meeting (San Diego). 2017. 11.
  6. Watanabe E, Gono T, Watanabe S, Yabe H, Kuwana M and Terai C: Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis. 2017 ACR/ARHP Annual Meeting (San Diego). 2017. 11.
  7. Shimizu T, Koga T, Horai, Y Fujikawa K, Endo Y, Tsuji S, Takatani A, Umeda M, Fukui S, Sumiyoshi R, Nishino A, Kawashiri S, Iwamoto N, Igawa T, T Ichinose K, Tamai, M NSakamoto N, Nakamura H, Origuchi T, Mukae H, Kuwana M and Kawakami A: Multiple Serum Cytokine and Chemokine Profiling to Identify Combinational Biomarkers Toward Patients of Polymyositis/Dermatomyositis Complicated with Rapidly Progressive Interstitial Lung Disease. 2017 ACR/ARHP Annual Meeting (San Diego). 2017. 11.
  8. Yamaguchi Y, Kuwana M, Kanaoka M, Watanabe T, Okiyama N, Gono T, Kodera M, Kambara T, Hamaguchi Y, Seishima M, Takehara K, Fujimoto M and Aihara M: HLA-DRB1*04:03/*04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population. 2017 ACR/ARHP Annual Meeting (San Diego). 2017. 11.
  9. 門田寛子、五野貴久、渡邉萌理、岡﨑有佳、福栄亮介、西川あゆみ、白井悠一郎、岳野光洋、寺井千尋、桑名正隆: 抗TIF1-γ抗体陽性の有無で見た悪性腫瘍関連筋炎の臨床的特徴.第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  10. 仁科直、川口鎮司、川上純、佐藤慎二、五野貴久、田村真麻、池田啓、布川貴博、金子祐子、桑名正隆: 間質性肺疾患を伴う多発性筋炎/皮膚筋炎における発症時期の地域性の検討. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  11. 五野貴久、川口鎮司、川上純、佐藤慎二、田村真麻、池田啓、布川貴博、金子祐子、仁科直、桑名正隆: 日常診療で測定可能な血清バイオマーカーを用いた多発性筋炎/皮膚筋炎合併間質性肺炎の予後の層別化に関する検討. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  12. 佐藤慎二、仁科直、川口鎮司、川上純、田村真麻、池田啓、布川貴博、金子祐子、五野貴久桑名正隆: 間質性肺炎を併発した多発性筋炎/皮膚筋炎の予後不良予測因子の検討. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  13. 渡邉萌理、五野貴久、杉谷直大、渡邊晋二、矢部寛樹、桑名正隆、寺井千尋: 多発性筋炎/皮膚筋炎における筋炎特異自己抗体別にみた寛解率に関する検討. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  14. 五野貴久: 筋炎特異的自己抗体は病原性を有するか. 第61回日本リウマチ学会総会・学術集会. (福岡). 2017. 4.
  15. 門田寛子、五野貴久、海野幸紀、福栄亮介、中島義雄、西川あゆみ、小林政司、白井悠一郎、岳野光洋、桑名正隆: 悪性黒色腫に対するニボルマブ投与後に皮膚筋炎が増悪した一例. 第58回関東リウマチ研究会. (東京). 2017. 7.
  16. 五野貴久、岡﨑有佳、桑名正隆: MESACUPTManti-MDA5テストと従来測定法による抗MDA5抗体測定結果の比較. 第45回日本臨床免疫学会総会. (東京). 2017. 9. 29.
  17. 渡邉駿介、白井悠一郎、岡﨑有佳、五野貴久、岳野光洋、桑名正隆: 抗KS抗体陽性患者では嚢胞性病変を伴う病変が多い. 第45回日本臨床免疫学会総会. (東京). 2017. 9.

2016年

論文(英文)
  1. Gono T, and Kuwana M. Choosing the right biomarkers to predict ILD in myositis. Nat. Rev. Rheumatol. 2016; 12(9): 504-506. doi:10.1038/nrrheum.2016.120
  2. Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M, and Kuwana M. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One. 2016; 11(4): e0154285. doi: 10.1371/journal.pone.0154285.
  3. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, and Aggarwal R. Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res. 2016; 68(5): 689-694. doi:
  4. Cao H, Xia Q, Pan M, Zhao X, Li X, Shi R, Ding X, Kuwana M, and Zheng J. Gottron’s papules and Gottron’s sign with ulceration: A distinctive cutaneous feature in a subset of DM/CADM patients. J. Rheumatol. 2016; 43(9): 1735-1742. doi: 10.3899/jrheum.160024.
  5. Fujimoto M, Murakami A, Kurei S, Okiyama N, Kawakami A, Mishima M, Sato S, Seishima M, Suda T, Mimori T, Takehara K, and Kuwana M. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 and anti-Mi-2 autoantibodies in dermatomyositis. J. Dermatol. Sci. 2016; 84(3): 272-281. doi: 10.1016/j.jdermsci.2016.09.013.
  6. Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M, Nakamura M, Tominaga M, Wakasugi D, Kawayama T, Kuwana M, Mimori T, Ida H, and Hoshino T. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. Respir. Invest. 2017; 55(1): 24-32. doi: 10.1016/j.resinv.2016.08.007.
  7. Naniwa T, Tamechika S, Okazaki Y, Maeda S, and Kuwana M. Coexistence of anti-melanoma differentiation-associated gene 5 and anti-aminoacyl-transfer RNA synthetase antibodies in a patient with dermatomyositis and rapidly progressive and relapsing interstitial lung disease. MR Case Rep. 2017; 1(1): 3-8. doi: 10.1080/24725625.2016.1253650.
  8. Uruha A, ishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, Suzuki S, Suzuki N, and Nishino I. Sarcoplasmic MxA expression -a marker highly diagnostic of dermatomyositis. Neurology. 2017; 88(5): 493-500. doi: 10.1212/WNL.0000000000003568.
  9. Matsushita T, Mizukami K, Kano M, Yagi M, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi Y, Murakami A, Hasegawa M, Kuwana M, Fujimoto M, and Takehara K. Anti-MDA5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br. J. Dermatol. 2017; 176(2): 395-402. doi: 10.1111/bjd.14882.
  10. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, and Aggarwal R. Anti-MDA5 autoantibody: expanding the clinical spectrum in North American dermatomyositis patients. J. Rheumatol. 2017; 44(3): 319-325. doi: 10.3899/jrheum.160682.
論文(和文)
  1. 五野貴久、寺井千尋: 多発性筋炎・皮膚筋炎の診療における最近の捉え方. 日本内科学会雑誌2016; 105(11): 2251-2258.
  2. 五野貴久: 多発性筋炎/皮膚筋炎と間質性肺炎. 科学評論社 リウマチ科 55(4): 370-376, 2016.
学会
  1. Moghadam-KS, Oddis CV, Sato S, Kuwana M, Aggarwa R. Anti-MDA5 Autoantibody: expanding the clinical spectrum in patients with dermatomyositis in North America. Annual European Congress of Rheumatology EULAR 2016 (London). 2016. 6.
  2. Kadota H, Shirai Y, Nagahama M, Okazaki O, Takeno M, Shimizu A, Kuwana M. In situ expression of transcriptional intermediary factor-1γ (TIF-1γ) in patients with cancerassociated myositis (CAM). The 13th international workshop no autoantibodies and autoimmunity (Kyoto). 2016. 10.
  3. Nishina1 N, Sato S, Kawaguchi Y, Kawakami A, Tamura M, Ikeda K, Nunokawa T, Tanino Y, Asakawa K, Kaneko Y, Gono T, Masui K, Kuwana M and JAMI investigators. Influence of Season and Residential Environment on Development of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis with Interstitial Lung Disease. 80th Annual Scientific Meeting of American College of Rheumatology (Washington, DC). 2016. 11.
  4. Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M, Ikeda K, Nunokawa T, Tanino Y, Asakawa K, Kaneko Y, Gono T, Kuwana M and JAMI investigators. Initial Predictors of Short-Term Poor Survival Rates in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease. 80th Annual Scientific Meeting of American College of Rheumatology (Washington, DC). 2016. 11.
  5. 桑名正隆: 多発性筋炎・皮膚筋炎スペクトラムにおける間質性肺疾患の多様性. 第56回日本呼吸器学会学術講演会. (京都). 2016. 4.
  6. 鏑木誠、白井悠一郎、岳野光洋、桑名正隆: 間質性肺疾患合併多発性筋炎/皮膚筋炎の胸部HRCTスコアリングによる検討. 第60回日本リウマチ学会総会・学術集会 (横浜). 2016. 4.
  7. 門田寛子、白井悠一郎、岡崎有佳、岳野光洋、桑名正隆: 抗TIF-1γ抗体陽性悪性腫瘍関連筋炎の臨床および病理組織学的特徴. 第60回日本リウマチ学会総会・学術集会 (横浜). 2016. 4.
  8. 仁科直、川口鎮司、川上純、佐藤慎二、五野貴久、田村真麻、池田啓、布川貴博、金子祐子、桑名正隆: 間質性肺疾患を伴う多発性筋炎/皮膚筋炎における発症時期の季節性の検討. 第60回日本リウマチ学会総会・学術集会 (横浜). 2016. 4.
  9. 藤本学、村上昭弘、榑井俊介、川上純、三嶋理晃、佐藤慎二、清島真理子、須田隆文、三森経世、竹原和彦、桑名正隆: 皮膚筋炎における抗TIF1γ抗体および抗Mi-2抗体のELISA検査試薬の有用性に関する検討. 第40回皮膚脈管・膠原病研究会. (福島). 2017. 1.

2015年

論文(英文)
  1. Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, Nakano N, Miyoshi M, Kinjo N, Murata T, Masunaga K, Umebayashi H, Imagawa T, Agematsu K, Sato S, Kuwana M, Yamada M, Yokota S, Koike K, and Ariga T. Cinical and laboratory features of fetal rapidly progressive interstitial lung diseases associated with juvenile dermatomyositis. Rheumatology. 2015; 54(5): 784-791. doi: 10.1093/rheumatology/keu385.
  2. Suzuki S, Nishiikawa A, Kuwana M, Nishimura H, Watanabe Y, Hayashi YK, Suzuki N, and Nishino I. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J. Rare Dis. 2015;10(1): 61. doi: 10.1186/s13023-015-0277-y.
  3. Hamada-Ode K, Taniguchi Y, Kimata T, Kawaguchi Y, Shimamura Y, Kuwana M, Fujimoto S, and Terada Y. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. Eur. J. Rheumatol. 2015; 2: 83-85. doi: 10.5152/eurjrheum.2015.0076.
  4. Chen Z, Hu W, Wang Y, Guo Z, Sun L, and Kuwana M. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clin. Rheumatol. 2015; 34(9): 1627-1631. doi: 10.1007/s10067-015-2935-9.
  5. Sato S, and Kuwana M. Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting. Int. J. Clin. Rheumatol. 2015; 10(4): 257-271. doi: 10.2217/ijr.15.27.
  6. Kawasumi H, Gono T, Kawaguchi Y, Kuwana M, Kaneko H, Katsumata Y, Kataoka S, Hanaoka M, and Yamanaka H. Clinical manifestations and myositis-specific autoantibodies associated with physical dysfunction after treatment in patients with polymyositis and dermatomyositis: An observational study of physical dysfunction with myosits in Japan. BioMed Res. Int. 2016; 2016: 9163201. doi: 10.1155/2016/9163201.
  7. Ma X, Chen Z, Hu W, Guo Z, Wang Y, Kuwana M, and Sun L. Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clin. Rheumatol. 2016; 35(2): 489-493. doi: 10.1007/s10067-015-3001-3.
論文(和文)
  1. 五野貴久. 炎症性筋症におけるサイトカインプロファイル. 科学評論社 リウマチ科 54(6): 645-650, 2015.
学会
  1. Chen Z, Y. Wang C, Kuwana M, Sun L. Clinical and Serological Features of Patients with Dermatomyositis Complicated by Spontaneous Pneumomediastinum. Annual European Congress of Rheumatology EULAR2015 (Roma). 2015. 6.
  2. Moghadam-K S, Oddis C.V, Sato S, Kuwana M and Aggarwa R. Clinical Characteristics of Anti-MDA5 (+) Dermatomyositis Patients in North America. 79th Annual Scientific Meeting of American College of Rheumatology (San Francisco). 2015. 11.